Flubromazepam Pure benzodiazepine research material from Raw Lab Chems
Buy Flubromazepam Pure Price range: € 90,00 through € 360,00
Back to products
Flubrotizolam Pellets thienotriazolodiazepine research material from Raw Lab Chems
Buy Flubrotizolam Pellets Price range: € 16,95 through € 299,95

Flubrotizolam 0.5 MG Fanax Bars

Price range: € 16,00 through € 472,39

Flubrotizolam FANAX Bars are described as molded laboratory research preparations associated with flubrotizolam, a brominated and fluorinated compound belonging to the thienotriazolodiazepine chemical family.

The compound is described as a structural analogue of brotizolam and is relevant to analytical investigations involving heterocyclic chemical identity, molecular characterization, and comparative examination of halogenated thienodiazepine derivatives.

The supplied information identifies a bar-shaped presentation but does not independently establish finished-unit composition, ingredient purity, or content uniformity.

Claims concerning HPLC verification, mass-spectrometric and NMR characterization, precision manufacturing, and protective packaging require supporting batch-specific documentation.

The FANAX designation is a catalog identifier and does not independently establish pharmaceutical authenticity or regulatory approval.

The material is not established as a certified reference standard or validated quantitative calibrator.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-13169 Category:
Description

Flubrotizolam FANAX Bars 0.5mg – Thienotriazolodiazepine Research Material

Product Overview

Flubrotizolam FANAX Bars are described in the supplied information as molded laboratory research preparations associated with flubrotizolam, a synthetic compound belonging to the thienotriazolodiazepine chemical family.

Flubrotizolam is characterized by a fused thienotriazolodiazepine framework containing brominated and fluorinated substituents.

The compound is described as a structural analogue of brotizolam.

These molecular characteristics provide a basis for scientific comparison of halogenated thienodiazepine derivatives and their analytical identification.

The supplied product is presented as a molded bar-shaped preparation under the FANAX designation.

Raw Lab Chems presents this material exclusively within a Research Use Only framework.

However, the product name and presentation do not independently establish chemical identity, ingredient purity, finished-unit composition, or content uniformity.

The source refers to analytical verification, precision manufacturing, and controlled packaging conditions.

These statements remain unverified until supported by documentation associated with the actual product and batch.

No clinical, therapeutic, diagnostic, veterinary, or consumer-oriented application is represented by this description.

Chemical Identity & Classification

Flubrotizolam is described as a synthetic compound belonging to the thienotriazolodiazepine chemical family.

Its proposed molecular structure includes a fused thiophene-associated diazepine framework and a triazole ring.

The source describes bromine and fluorine substituents as distinguishing structural features.

The supplied source provides the following chemical-reference information:

  • Common name: Flubrotizolam
  • Catalog designation: FANAX Bars
  • Reported systematic name: 2-Bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine
  • Chemical classification: Brominated and fluorinated thienotriazolodiazepine
  • Reported molecular formula: C15H10BrFN4S
  • Structural relationship: Brotizolam analogue

No CAS Registry Number or molecular weight was supplied in this product description.

These identifiers are reproduced from the source and do not independently establish the composition of the actual product.

The source does not provide a verified salt-form designation or complete formulation specification.

The molecular formula describes the named compound rather than the entire molded preparation.

A finished bar may contain additional formulation ingredients that are not represented by the formula.

Researchers seeking public chemical-reference information may consult PubChem and confirm that any selected database entry corresponds to the intended compound and chemical form.

Chemical & Physical Characteristics

The supplied product is described as a precision-molded analytical bar.

No product-specific inspection report, bar-dimension specification, excipient list, or formulation-characterization record was provided.

The stated physical presentation therefore remains a source-provided description.

The flubrotizolam molecular framework contains a fused thienotriazolodiazepine ring system with brominated and fluorinated substituents.

These structural features provide a basis for analytical differentiation from related benzodiazepine and thienodiazepine derivatives.

However, structural similarity does not establish identical physical properties, stability, impurity profiles, or analytical behavior.

The source identifies molecular stability, halogen substitution, and comparative structural characterization as scientific topics.

No product-specific degradation measurements, stability data, or experimentally verified physicochemical profile accompanied this description.

The source also does not provide a verified melting point, quantitative solubility profile, density, hardness, friability, or hygroscopicity measurement.

The finished molded preparation may contain additional formulation ingredients.

No verified bar dimensions, total unit mass, excipient composition, component distribution, or content-uniformity measurements accompanied the supplied information.

The source recommends cool, dry storage protected from ultraviolet light.

No validated stability study or experimentally established shelf-life specification accompanied this recommendation.

Purity & Analytical Verification

The supplied description claims ingredient purity of at least 98%, with HPLC and NMR cited as verification methods.

It also refers to mass spectrometry for structural identification and precision manufacturing for finished-unit consistency.

However, no actual batch-specific Certificate of Analysis, chromatogram, mass spectrum, NMR spectrum, or independent laboratory report was provided.

Accordingly, the stated purity threshold is not independently confirmed for the material described here.

The source identifies LC-MS and GC-MS as analytical techniques associated with flubrotizolam investigation.

Such methods may provide information concerning chemical identity, structural characteristics, impurity profiles, and analytical specificity.  Flubrotizolam FANAX Bars 0.5mg

However, naming an analytical technique does not establish that it was performed on the actual product.

An important distinction exists between the purity of the chemical ingredient and the composition of the finished molded bar.

Even if ingredient purity were independently established, that finding would not by itself verify the labeled component amount, total formulation, or consistency between individual units.

The source also references comparative chemical studies involving related halogenated thienotriazolodiazepines.

These references provide scientific context rather than evidence of the product’s verified performance in a particular laboratory method.

No certified reference-material status, validated finished-unit content, or independently established purity specification is asserted.

Quality Control & Batch Integrity

The supplied source claims that individual batches undergo HPLC testing to confirm purity and labeled component content.  Flubrotizolam FANAX Bars 0.5mg

It also describes mass-spectrometric verification, NMR characterization, and manufacturing controls intended to support uniformity between individual bars.

No actual certificate, independent testing record, manufacturing audit, laboratory accreditation document, or batch-specific quality-control report accompanied these statements.

They therefore remain unverified supplier claims.

For reproducible laboratory investigation, useful records may include supplier identification, batch number, chemical identifier, receipt date, storage history, and available analytical findings.

For molded preparations, the identity and purity of the named ingredient should be distinguished from the composition and consistency of the finished units.

The supplied information does not establish independently verified content uniformity, excipient composition, or quantitative accuracy of the labeled amount.

Where a material is described as suitable for reference-standard work, researchers should distinguish ordinary catalog material from a certified reference material.

The supplied information does not establish certified reference-material status, metrological traceability, or an assigned measurement uncertainty.

Claims of consistent purity, identity, formulation quality, or manufacturing compliance should be supported by actual analytical records rather than inferred from catalog terminology.  Flubrotizolam FANAX Bars 0.5mg

Safety, Handling & Laboratory Precautions

Flubrotizolam is a benzodiazepine-related compound requiring appropriate institutional risk assessment and controlled laboratory handling.

Its structural relationship to other thienotriazolodiazepines does not establish a verified product-specific toxicological profile.

Research personnel should consult applicable chemical-safety documentation and institutional procedures before receiving or examining the material.

Laboratory precautions should address access restrictions, protective equipment, contamination prevention, accidental exposure, environmental release, and chemical-waste disposal.

The compound’s relationship to other benzodiazepine derivatives does not establish safety for human or veterinary exposure.

The material should remain secured against unauthorized access and separated from food, beverages, and non-research environments.  Flubrotizolam FANAX Bars 0.5mg

Because the actual purity and finished-unit composition have not been independently confirmed, laboratory documentation should distinguish verified characteristics from supplier-provided statements.

The FANAX designation and bar-shaped presentation must not be interpreted as evidence of pharmaceutical suitability or authorization for personal use.

Any accidental exposure or contamination incident should be managed according to institutional emergency procedures.

Packaging, Labeling & Storage

The supplied source describes moisture-resistant, light-shielded packaging intended to protect material integrity during transportation.

No packaging-validation study, verified container specification, or actual shipment-condition record accompanied this claim.  Flubrotizolam FANAX Bars 0.5mg

The source recommends cool, dry storage protected from direct ultraviolet light, with a suggested temperature range of 15–25°C.

No validated stability data was provided to establish that this temperature range is necessary or sufficient for a particular shelf life.

The source also claims that shipping arrangements support international laboratory requirements.

No shipment classification, carrier documentation, or destination-specific regulatory authorization was supplied to substantiate those statements.

Laboratory inventory records should preserve the compound name, any available batch identifier, receipt details, and relevant storage observations.

The labeled bar content should be recorded as a source-provided specification unless independently confirmed.

Where chemical form or formulation ingredients remain uncertain, the inventory record should preserve those uncertainties rather than assign unverified details. Flubrotizolam FANAX Bars 0.5mg

Packaging and environmental requirements should be assessed using available safety documentation, relevant stability evidence, and institutional laboratory procedures.

Intended Research Use & Market Positioning

The supplied scientific context places flubrotizolam within analytical research involving thienotriazolodiazepine derivatives, chemical identification, structural comparison, and forensic toxicology.

Its brominated and fluorinated molecular framework provides a basis for differentiating it from related compounds in appropriately validated analytical investigations.

The source references chromatographic identification, mass-spectrometric characterization, and comparative examination of halogenated heterocyclic structures.

These references describe laboratory research contexts and do not establish any human-use application.

The supplied Raw Lab Chems catalog includes Flubrotizolam FANAX Bars, corresponding to the preparation discussed here.

The catalog also includes Flubrotizolam Pellets, a differently presented product associated with the same named compound.  Flubrotizolam FANAX Bars 0.5mg

The supplied information does not establish whether these two listings share identical chemical forms, ingredient purity, finished-unit composition, or analytical characteristics.

These references provide chemical-catalog context rather than evidence of certified reference-material status or interchangeability.

Ordering, Availability & Fulfillment

The supplied source describes standardized laboratory units, protective packaging, and professional international shipping arrangements.

However, no current inventory information, carrier record, destination-specific authorization, or verified shipment-performance documentation was provided.

Consequently, no specific availability, delivery, customs-clearance, or transportation-compliance guarantee is asserted.

Flubrotizolam may be subject to controlled-substance, analogue, pharmaceutical, or other chemical regulations depending on the jurisdiction.

Institutional acquisition and transfer should therefore be assessed against the applicable laws governing the exact substance and chemical form involved.  Flubrotizolam FANAX Bars 0.5mg

Researchers and institutions should independently verify whether possession, importation, exportation, transportation, and laboratory investigation are authorized in their jurisdictions.

Research-only labeling does not establish an exemption from controlled-substance regulations.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flubrotizolam is a thienotriazolodiazepine-related compound whose acquisition, possession, transfer, importation, exportation, storage, and laboratory investigation may be restricted or prohibited under applicable controlled-substance, analogue, pharmaceutical, or other chemical regulations.

The exact legal classification and requirements may vary by jurisdiction.

Researchers and institutions remain responsible for determining the applicable legal requirements and obtaining any necessary authorizations.  Flubrotizolam FANAX Bars 0.5mg

No medical approval, consumer-use authorization, universal legal status, or regulatory exemption is implied by this description.

Additional information
Quantity

10 pellets

,

25 pellets

,

50 pellets

,

100 pellets

,

250 pellets

,

500 pellets

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Flubrotizolam 0.5 MG Fanax Bars”
Shipping & Delivery